A recent meta-analysis that included 1646 patients with CKD showed that adding a mineralocorticoid receptor antagonist to the classic RAAS blockade produced an additional reduction in proteinuria of 38.7%; however patients were three times more likely to develop hypercalemia [33]. The gene discussed is NR3C2; the disease is chronic kidney disease.